NEOFORDEX Trademark

Trademark Overview


On Friday, January 31, 2014, a trademark application was filed for NEOFORDEX with the United States Patent and Trademark Office. The USPTO has given the NEOFORDEX trademark a serial number of 79144403. The federal status of this trademark filing is IR CANCELLED - US REGISTRATION CANCELLED as of Thursday, February 1, 2024. This trademark is owned by LABORATOIRES C.T.R.S.. The NEOFORDEX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and veterinary products for treating progression of chronic diseases, proliferative diseases, and for treating rheumatological diseases; pharmaceutical and veterinary products for treating oncological diseases, especially colon cancer, rectum cancer, breast cancer, prostate cancer, pancreatic cancer, gastric cancer, thyroid cancer, larynx cancer, liver cancer, uterine cancer, cervical cancer, esophagus cancer, ovarian cancer, lung cancer, pleural cancer, oral cavity cancer, kidney cancer, bladder cancer, testicular cancer, melanoma, lymphatic cancer, hematopoietic cancer, carcinoma, sarcoma, nervous system cancer, particularly primary tumors; pharmaceutical and veterinary products for treating onco-haematological diseases, especially lymphomas, especially Hodgkin's disease and non-Hodgkin lymphomas, lymphadenopathy, myeloma, especially multiple myeloma, and leukemia; pharmaceutical and veterinary products for treating haematological diseases, especially amyloses, and pur...
neofordex

General Information


Serial Number79144403
Word MarkNEOFORDEX
Filing DateFriday, January 31, 2014
Status404 - IR CANCELLED - US REGISTRATION CANCELLED
Status DateThursday, February 1, 2024
Registration Number4705767
Registration DateTuesday, March 24, 2015
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 6, 2015

Trademark Statements


Goods and ServicesPharmaceutical and veterinary products for treating progression of chronic diseases, proliferative diseases, and for treating rheumatological diseases; pharmaceutical and veterinary products for treating oncological diseases, especially colon cancer, rectum cancer, breast cancer, prostate cancer, pancreatic cancer, gastric cancer, thyroid cancer, larynx cancer, liver cancer, uterine cancer, cervical cancer, esophagus cancer, ovarian cancer, lung cancer, pleural cancer, oral cavity cancer, kidney cancer, bladder cancer, testicular cancer, melanoma, lymphatic cancer, hematopoietic cancer, carcinoma, sarcoma, nervous system cancer, particularly primary tumors; pharmaceutical and veterinary products for treating onco-haematological diseases, especially lymphomas, especially Hodgkin's disease and non-Hodgkin lymphomas, lymphadenopathy, myeloma, especially multiple myeloma, and leukemia; pharmaceutical and veterinary products for treating haematological diseases, especially amyloses, and purpura, especially thrombocytopenic purpura; pills, capsules, tablets, and powders pertaining to healthy diet for use in treating oncological diseases; chemical preparations for medical and pharmaceutical use for treating progression of chronic diseases, proliferative disease, and for treating rheumatological diseases; chemical preparations for medical and pharmaceutical use for treating oncological diseases, especially colon cancer, rectum cancer, breast cancer, prostate cancer, pancreatic cancer, gastric cancer, thyroid cancer, larynx cancer, liver cancer, uterine cancer, cervical cancer, esophagus cancer, ovarian cancer, lung cancer, pleural cancer, oral cavity cancer, kidney cancer, bladder cancer, testicular cancer, melanoma, lymphatic cancer, hematopoietic cancer, carcinoma, sarcoma, nervous system cancer, particularly primary tumors; chemical preparations for medical and pharmaceutical use for treating onco-haematological diseases, especially lymphomas, especially Hodgkin's disease and non-Hodgkin lymphomas, lymphadenopathy, myeloma, especially multiple myeloma, and leukemia; chemical preparations for medical and pharmaceutical use for treating haematological diseases, especially amyloses, and purpura, especially thrombocytopenic purpura
Pseudo MarkNEO FORDEX

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, November 26, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTHERAVIA
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressFR

Party NameLABORATOIRES C.T.R.S.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressFR

Party NameLABORATOIRES C.T.R.S.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressFR

Trademark Events


Event DateEvent Description
Thursday, March 27, 2014SN ASSIGNED FOR SECT 66A APPL FROM IB
Tuesday, April 29, 2014ASSIGNED TO EXAMINER
Friday, October 31, 2014CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, March 28, 2014NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, April 1, 2014APPLICATION FILING RECEIPT MAILED
Thursday, May 1, 2014NON-FINAL ACTION WRITTEN
Friday, May 2, 2014NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, May 2, 2014REFUSAL PROCESSED BY MPU
Friday, May 2, 2014NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, May 23, 2014REFUSAL PROCESSED BY IB
Friday, October 31, 2014TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, November 1, 2014TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, November 4, 2014EXAMINER'S AMENDMENT ENTERED
Tuesday, November 4, 2014EXAMINERS AMENDMENT -WRITTEN
Tuesday, November 4, 2014EXAMINERS AMENDMENT E-MAILED
Tuesday, November 4, 2014NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, December 17, 2014NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, December 17, 2014NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, December 17, 2014NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Tuesday, November 4, 2014APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, November 22, 2014ASSIGNED TO LIE
Monday, December 1, 2014LAW OFFICE PUBLICATION REVIEW COMPLETED
Saturday, January 3, 2015NOTIFICATION PROCESSED BY IB
Tuesday, January 6, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 24, 2015REGISTERED-PRINCIPAL REGISTER
Wednesday, June 24, 2015FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Friday, September 18, 2015FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, January 6, 2015PUBLISHED FOR OPPOSITION
Saturday, June 6, 2015NEW REPRESENTATIVE AT IB RECEIVED
Thursday, July 30, 2015FINAL DISPOSITION PROCESSED
Thursday, July 30, 2015FINAL DISPOSITION NOTICE SENT TO IB
Wednesday, September 7, 2022INVALIDATION PROCESSED
Friday, November 15, 2019NEW REPRESENTATIVE AT IB RECEIVED
Tuesday, March 24, 2020COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Thursday, May 7, 2020NEW REPRESENTATIVE AT IB RECEIVED
Friday, November 26, 2021CANCELLED SECTION 71
Tuesday, July 26, 2022TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Sunday, October 2, 2022TOTAL INVALIDATION PROCESSED BY THE IB
Wednesday, September 7, 2022TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Monday, February 12, 2024CHANGE OF NAME/ADDRESS REC'D FROM IB
Saturday, August 17, 2024DEATH OF INTERNATIONAL REGISTRATION
Saturday, August 17, 2024NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED